1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, January 2019 (p2)

Cancer Analysis & Statistics in European Union, January 2019 (p2)

31-60 of about 100 reports

Revlimid

Revlimid

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewRevlimid (lenalidomide; Celgene) is an oral thalidomide analog with antineoplastic, immunomodulatory, and anti-angiogenic properties. Studies have shown that Revlimid inhibits the growth of ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
lisocabtagene maraleucel

lisocabtagene maraleucel

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewLisocabtagene maraleucel (also known as JCAR017; Celgene) will be the third autologous chimeric antigen receptor T-cell (CAR-T) therapy to reach the diffuse large B-cell lymphoma (DLBCL) market ...

  • Industries : Cancer, Medical Biotechnology, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
umbralisib

umbralisib

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewUmbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Yescarta

Yescarta

  • $ 10000
  • Industry report
  • January 2019

Drug OverviewYescarta (axicabtagene ciloleucel; Gilead) became the first chimeric antigen receptor T-cell (CAR-T) therapy to launch for the treatment of diffuse large B-cell lymphoma (DLBCL) when it gained ...

  • Industries : Medical Biotechnology, Cancer, Pathology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

HR+/HER2- Breast Cancer Pricing, Reimbursement, and Access

  • $ 2995
  • Industry report
  • October 2018

Spend on breast cancer medicines is a high-level concern for payers, but few access restrictions are in placeDespite a high level of concern regarding spend on breast cancer medicines, access restrictions ...

  • Industries : Cancer
  • Countries : United States, European Union, Japan
NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence

NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034, Pharma Intelligence

  • $ 22000
  • Industry report
  • October 2018

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin’s lymphoma (NHL), accounting for about one-third ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Blincyto

Blincyto

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewBlincyto (blinatumomab; Amgen/AstraZeneca/Astellas), produced in Chinese hamster ovary cells, is a bispecific T-cell engager that directs T-cells to target CD19-positive benign and malignant ...

  • Industries : Medical Biotechnology, Biopharmaceutical, Biopharmaceutical, Cancer
  • Countries : United States, Japan, European Union
polatuzumab vedotin

polatuzumab vedotin

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewPolatuzumab vedotin (Roche) is an antibody-drug conjugate (ADC) that combines a humanized immunoglobulin (Ig)-G1 monoclonal antibody (MAb) targeting human B-cell surface antigen cluster of ...

  • Industries : Therapy, Medical Biotechnology, Oncology, Biopharmaceutical, Biopharmaceutical
  • Countries : United States, Japan, European Union
Selinexor

Selinexor

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewSelinexor (Karyopharm Therapeutics/Ono Pharmaceutical) selectively inhibits the transport protein exportin-1 (XPO1), also called chromosome region maintenance-1. XPO1 is responsible for the ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, Japan, European Union
Bavencio

Bavencio

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewBavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
MOR208

MOR208

  • $ 10000
  • Industry report
  • October 2018

Drug OverviewMorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible ...

  • Industries : Medical Biotechnology, Therapy, Biopharmaceutical, Biopharmaceutical, Cancer
  • Countries : United States, European Union
The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

The Latest in Immuno-Oncology: A Deep Dive into Non-Small Cell Lung Cancer (NSCLC)

  • $ 3000
  • Industry report
  • October 2018

Highlights:New therapies are emerging that harness the immune system to treat cancer, with the PD-1/L1 inhibitor class at the forefrontTrial activity within NSCLC is particularly intense, as Opdivo and ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Colorectal Cancer Forecast and Market Analysis to 2036, Pharma Intelligence

Colorectal Cancer Forecast and Market Analysis to 2036, Pharma Intelligence

  • $ 22000
  • Industry report
  • September 2018

Disease OverviewColorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiato ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035, Pharma Intelligence

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035, Pharma Intelligence

  • $ 22000
  • Industry report
  • August 2018

Disease OverviewLung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancer (NSCLC), with the exact proportion depending ...

  • Industries : Cancer, Pathology
  • Countries : European Union, United States, Japan
Gilotrif

Gilotrif

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewGilotrif (afatinib; Boehringer Ingelheim) is an orally administered tyrosine kinase inhibitor (TKI) that irreversibly binds to epidermal growth factor receptor (EGFR)/human epidermal growth ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Cemiplimab

Cemiplimab

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewCemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody. The interaction between PD-1 and its ligand PD-L1 on a T cell reduces T-cell function signals, resulting ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Dacomitinib

Dacomitinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewDacomitinib is a small-molecule, irreversible inhibitor of HER1, HER2, and HER4, under development by Pfizer. Mutation or amplification of the HER gene is seen in several malignancies including ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Entrectinib

Entrectinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewEntrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins. ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Vargatef

Vargatef

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewVargatef (nintedanib; Boehringer Ingelheim) is a triple angiokinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), ...

  • Industries : Cancer, Pathology
  • Countries : European Union
Tafinlar

Tafinlar

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewTafinlar (dabrafenib; Novartis) is an adenosine triphosphate-competitive BRAF inhibitor with more than 100-fold selectivity for mutated BRAF over wild-type. BRAF is part of the mitogen-activated ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Iressa

Iressa

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewIressa (gefitinib; AstraZeneca) is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase domain. The receptor is expressed on the cell surface of both normal ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Tagrisso

Tagrisso

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewTagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) inhibitor developed by AstraZeneca. Tagrisso has shown clinical activity against the EGFR T790M mutation, ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Abraxane

Abraxane

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAbraxane (nab-paclitaxel; Celgene/Taiho) is an albumin-bound formulation of paclitaxel, an antimicrotubule taxane that interferes with the growth of tumors by inhibiting mitosis during metaphase. ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Tarceva

Tarceva

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewTarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. EGFR is part of the ErbB pathway, which is hyperactivated ...

  • Industries : Cancer, Pathology, Therapy
  • Countries : United States, Japan, European Union
Seribantumab

Seribantumab

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewSeribantumab (Merrimack Pharmaceuticals) is a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3), also known as ErbB3. HER3 is a member of the epidermal growth ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Lorlatinib

Lorlatinib

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewLorlatinib (Pfizer) is an orally administered anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinase inhibitor (TKI) with potential antineoplastic activity. Genetic alterations to ROS1 ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Xalkori

Xalkori

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewXalkori (crizotinib; Pfizer/Merck KGaA) is a selective, adenosine triphosphate-competitive small molecule multi-kinase inhibitor of mesenchymal epithelial transition growth factor (c-Met o ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Zykadia

Zykadia

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewZykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Alecensa

Alecensa

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAlecensa (alectinib) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Roche and Chugai. In some non-small cell lung cancer (NSCLC) patients, abnormal ALK configuration ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Alimta

Alimta

  • $ 10000
  • Industry report
  • August 2018

Drug OverviewAlimta (pemetrexed; Eli Lilly) is an antifolate antineoplastic agent that exerts its action by disrupting folate-dependent metabolic processes essential for cell replication. Similar to fluorouracil, ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
About 200 reports

Download Unlimited Documents from Trusted Public Sources

CT Scan Industry in EU

  • September 2019
    6 pages
  • CT Scan  

    Lung Cancer  

  • European Union  

View report >

Cancer Statistics January 2019


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on